Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-26-166693
Filing Date
2026-04-21
Accepted
2026-04-21 16:00:11
Documents
11

Document Format Files

Seq Description Document Type Size
1 DEFA14A trvi-20260421.htm   iXBRL DEFA14A 32142
2 GRAPHIC img92490068_0.jpg GRAPHIC 515038
3 GRAPHIC img92490068_1.jpg GRAPHIC 421865
  Complete submission text file 0001193125-26-166693.txt   2208822

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20260421.xsd EX-101.SCH 7443
14 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20260421_htm.xml XML 1301
Mailing Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38886 | Film No.: 26879233
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)